دورية أكاديمية
أعرض في EDS

The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature.

التفاصيل البيبلوغرافية
العنوان: The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature.
المؤلفون: Carneiro A; Department of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil.; Department of Pathology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Barbosa ÁRG; Department of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Takemura LS; Department of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Kayano PP; Department of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Moran NKS; Department of Pathology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Chen CK; Department of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Wroclawski ML; Department of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil.; Department of Pathology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Lemos GC; Department of Urology, Hospital Israelita Albert Einstein, São Paulo, Brazil., da Cunha IW; Department of Pathology, Rede D'OR São Luiz, São Paulo, Brazil., Obara MT; Department of Pathology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Tobias-Machado M; Department of Pathology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Sowalsky AG; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Bianco B; Human Reproduction and Genetics Center, Faculdade de Medicina do ABC, Santo André, Brazil.
المصدر: Frontiers in oncology [Front Oncol] 2018 Sep 18; Vol. 8, pp. 377. Date of Electronic Publication: 2018 Sep 18 (Print Publication: 2018).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مستخلص: Background: Prostate cancer (PCa) is a heterogeneous disease that lends itself toward numerous therapeutic options depending on its risk stratification. One of the greatest challenges in PCa urologic practice is to select patients who should be referred for biopsy and, for those patients who are diagnosed with cancer, to differentiate between patients with indolent disease from those with an unfavorable prognosis and, to determine ideal patient management and avoid unnecessary interventions. Accordingly, there is a growing body of literature reporting immunohistochemical studies with the objective of determining a prostate cancer prognosis. Among the most frequent biomarkers studied are Ki-67, p53, PTEN, MYC, and ERG. Based on these findings, we systematically reviewed articles that assessed the role of these main prognostic markers in prostate cancer. Methods: Consistent with PRISMA guidelines, we performed a systematic literature search throughout the Web of Science and PubMed Medline databases. We considered all types of studies evaluating the role of Ki-67, p53, PTEN, MYC, and ERG immunohistochemical analysis in prostate cancer until July 2017. Results: We identified 361 articles, 44 of which were summarized in this review. Diagnostically, no single immunohistochemical marker was able to define a tumor as benign or malignant. Prognostically, Ki-67, p53, and MYC were related to the tumor grade given by Gleason score and to the tumor stage (higher levels related to higher tumor grade). Furthermore, Ki-67 was also related to higher PSA levels, shorter disease-free intervals and shorter tumor-specific survival; the latter was also related to p53. The loss of PTEN protein expression showed a higher association with biochemical recurrence and with a worse prognosis, beyond that predicted by the Gleason score and tumor stage. ERG staining also showed a strong association with biochemical recurrence. Conclusion: There are several studies relating immunohistochemical markers with clinical-laboratorial outcomes in prostate cancer, the most frequent being Ki-67, p53, ERG, PTEN, and MYC. However, none of these markers have been validated by literary consensus to be routinely applied in medical practice.
References: Br J Cancer. 2013 Jun 25;108(12):2582-9. (PMID: 23695019)
Mod Pathol. 2016 Feb;29(2):143-56. (PMID: 26612463)
Prostate. 2003 Apr 1;55(1):20-9. (PMID: 12640657)
Int Urol Nephrol. 2013 Jun;45(3):727-33. (PMID: 23686669)
Br J Cancer. 2007 Jan 15;96(1):82-8. (PMID: 17146477)
J Urol. 1974 Jan;111(1):58-64. (PMID: 4813554)
Eur Urol. 2017 May;71(5):697-700. (PMID: 27477529)
Clin Cancer Res. 2012 May 15;18(10):2896-904. (PMID: 22452941)
Clin Cancer Res. 1999 Aug;5(8):2082-8. (PMID: 10473090)
Asian Pac J Cancer Prev. 2016;17(5):2655. (PMID: 27268646)
Am J Pathol. 1996 May;148(5):1557-65. (PMID: 8623924)
Prostate. 2013 Sep;73(13):1371-7. (PMID: 23661613)
Transl Oncol. 2016 Dec;9(6):575-582. (PMID: 27916292)
Urology. 2005 Aug;66(2):332-7. (PMID: 16098362)
Clin Cancer Res. 2011 Oct 15;17(20):6563-73. (PMID: 21878536)
JAMA. 2017 Mar 21;317(11):1141-1150. (PMID: 28324092)
Korean J Pathol. 2012 Oct;46(5):423-8. (PMID: 23136568)
Mod Pathol. 2016 Dec;29(12):1565-1574. (PMID: 27562498)
PLoS One. 2013 May 30;8(5):e63941. (PMID: 23737958)
Hum Pathol. 1998 Sep;29(9):949-54. (PMID: 9744310)
Prostate. 2016 Jun;76(9):845-53. (PMID: 27159573)
Ann Intern Med. 2012 Jul 17;157(2):120-34. (PMID: 22801674)
Virchows Arch. 2014 Mar;464(3):293-300. (PMID: 24487790)
N Engl J Med. 2009 Mar 26;360(13):1310-9. (PMID: 19297565)
J Clin Urol. 2016 Dec;9(2 Suppl):3-10. (PMID: 28344810)
Eur Urol. 2016 Dec;70(6):954-960. (PMID: 27329565)
Oncology (Williston Park). 2017 May 15;31(5):333-40, 345. (PMID: 28512731)
J Urol. 2018 Mar;199(3):683-690. (PMID: 29203269)
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):230-3. (PMID: 23271778)
Prostate Cancer Prostatic Dis. 2013 Jun;16(2):132-8. (PMID: 23381693)
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. (PMID: 24083995)
Asian J Androl. 2017 Jul-Aug;19(4):458-462. (PMID: 27232854)
Oncogene. 2016 Jan 28;35(4):403-14. (PMID: 25915839)
Int J Clin Exp Pathol. 2015 Feb 01;8(2):1878-88. (PMID: 25973080)
N Engl J Med. 2016 Oct 13;375(15):1415-1424. (PMID: 27626136)
Future Sci OA. 2015 Dec 17;2(1):FSO72. (PMID: 28031932)
Mod Pathol. 2012 Mar;25(3):471-9. (PMID: 22080055)
Eur Urol Focus. 2016 Jun;2(2):180-188. (PMID: 27617307)
N Engl J Med. 2012 Jul 19;367(3):203-13. (PMID: 22808955)
JAMA. 2018 Mar 6;319(9):883-895. (PMID: 29509864)
Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):594-600. (PMID: 24515272)
PLoS One. 2015 Apr 21;10(4):e0122498. (PMID: 25897494)
Mod Pathol. 2008 Sep;21(9):1156-67. (PMID: 18567993)
Am J Clin Pathol. 2014 Oct;142(4):533-40. (PMID: 25239421)
Clin Cancer Res. 2003 Apr;9(4):1474-9. (PMID: 12684422)
J Natl Cancer Inst. 2015 Nov 27;108(2):. (PMID: 26615022)
Int J Cancer. 2005 Feb 10;113(4):619-28. (PMID: 15472903)
Prostate Int. 2016 Dec;4(4):130-135. (PMID: 27995111)
Prostate. 2015 Aug 1;75(11):1216-26. (PMID: 25939480)
Jpn J Clin Oncol. 2011 Apr;41(4):555-64. (PMID: 21233104)
Eur Urol. 2015 Apr;67(4):795-802. (PMID: 25454616)
Diagn Pathol. 2016 Mar 09;11:25. (PMID: 26956509)
Biotechnol Adv. 2017 Mar - Apr;35(2):135-149. (PMID: 27939303)
N Engl J Med. 2009 Mar 26;360(13):1320-8. (PMID: 19297566)
Int J Cancer. 2009 May 1;124(9):2116-23. (PMID: 19117060)
JAMA Oncol. 2016 Nov 1;2(11):1505-1507. (PMID: 27356204)
BMC Cancer. 2017 Feb 24;17(1):157. (PMID: 28235401)
Hum Pathol. 2014 Mar;45(3):488-97. (PMID: 24406017)
Hum Pathol. 2015 May;46(5):698-706. (PMID: 25724568)
J Urol. 1998 Dec;160(6 Pt 2):2407-11. (PMID: 9817393)
Br J Cancer. 2016 Apr 12;114(8):939-44. (PMID: 26986253)
Virchows Arch. 2017 Dec;471(6):753-759. (PMID: 28550496)
Int J Urol. 2017 May;24(5):352-360. (PMID: 28345187)
Neoplasma. 2015;62(2):278-87. (PMID: 25591593)
J Urol. 2017 Apr;197(4):1054-1059. (PMID: 27693448)
BJU Int. 2009 Jul;104(1):20-4. (PMID: 19239456)
Mod Pathol. 2015 Jan;28(1):128-137. (PMID: 24993522)
PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
PLoS One. 2015 Jul 14;10(7):e0132343. (PMID: 26172920)
Prostate. 2014 Nov;74(15):1481-7. (PMID: 25175352)
فهرسة مساهمة: Keywords: ERG; Ki-67; MYC; PTEN; biomarkers; immunohistochemistry; p53; prostate cancer
تواريخ الأحداث: Date Created: 20181004 Latest Revision: 20201001
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC6153326
DOI: 10.3389/fonc.2018.00377
PMID: 30280090
قاعدة البيانات: MEDLINE
الوصف
تدمد:2234-943X
DOI:10.3389/fonc.2018.00377